Substance / Medication

Hydroflumethiazide

Overview

Active Ingredient
hydroflumethiazide
RxNorm CUI
5495

Indications

Saluron® is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis and corticosteroid and estrogen therapy. Saluron® has also been found useful in edema due to various forms of renal dysfunction, such as nephrotic syndrome, acute glomerulonephritis, and chronic renal failure. Saluron® is indicated in the management of hypertension, either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in t

Labeler: ShireUpdated: 2006-07-19T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Saluron® is contraindicated in patients with anuria or hypersensitivity to this or other sulfonamide-derived drugs.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

Research Evidence

Published studies and systematic reviews

Sort:
Intensive Blood Pressure Control in Type 2 Diabetes: A Systematic Review and Meta-Analysis of Cardiovascular and Microvascular Outcomes.
Mousavi Asma, Shojaei Shayan, Abhari Amir Parsa et al. · Am J Hypertens · 2026
PMID: 40717314Meta-Analysis
The Effect of SGLT2 Inhibitors on Blood Pressure in Relation to Baseline Kidney Function: A Systematic Literature Review and Data Analysis.
Møller Charlotte Agergaard, Nielsen Steffen Flindt, Mose Frank Holden · Am J Hypertens · 2026
PMID: 40717316Meta-Analysis
PLA2R autoantibodies, a multifaceted biomarker in nephrotic syndrome and membranous nephropathy.
Ragy Omar, Abass Wessam, Kanigicherla Durga Anil K et al. · Nephrol Dial Transplant · 2025
PMID: 39820570Meta-AnalysisFull text (PMC)
Biomarkers to predict or measure steroid resistance in idiopathic nephrotic syndrome: A systematic review.
May Carl J, Ford Nathan P, Welsh Gavin I et al. · PLoS One · 2025
PMID: 39946431Meta-AnalysisFull text (PMC)
Interventions for idiopathic steroid-resistant nephrotic syndrome in children.
Liu Isaac D, Willis Narelle S, Craig Jonathan C et al. · Cochrane Database Syst Rev · 2025
PMID: 40337980Meta-AnalysisFull text (PMC)
Kidney function and mortality in childhood nephrotic syndrome.
Robinson Cal H, Ogome Bess-Joan, Selvathesan Nithiakishna et al. · Nephrol Dial Transplant · 2025
PMID: 40600975Meta-Analysis
Impact of tumor necrosis factor-alpha gene variant in pediatric nephrotic syndrome: a meta-analysis.
Venkatachalapathy Yogalakshmi, Suresh Praveenkumar Kochuthakidiyel, Balraj Thendral Hepsibha et al. · Sci Rep · 2025
PMID: 40813446Meta-AnalysisFull text (PMC)
Use of urinary NGAL in steroid-resistant vs. steroid-sensitive nephrotic syndrome: a systematic review and meta-analysis.
Abdalla Aymen, Ali Abdelrahman, Abufatima I O et al. · BMC Nephrol · 2025
PMID: 40849613Meta-AnalysisFull text (PMC)
Corticosteroid therapy for nephrotic syndrome in children.
Hahn Deirdre, Samuel Susan M, Willis Narelle S et al. · Cochrane Database Syst Rev · 2024
PMID: 39171624Meta-AnalysisFull text (PMC)
Non-corticosteroid immunosuppressive medications for steroid-sensitive nephrotic syndrome in children.
Larkins Nicholas G, Hahn Deirdre, Liu Isaac D et al. · Cochrane Database Syst Rev · 2024
PMID: 39513526Meta-AnalysisFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Health Goals

Goals connected through associated conditions

Quick Facts

Type
Substance / Medication
Fully Specified Name
Hydroflumethiazide (substance)
SNOMED CT
395946004
UMLS CUI
C0020273
RxNorm CUI
5495
Labeler
Shire

Clinical Data

This intervention maps to 13 entities in the Ltrl knowledge graph.

6
Conditions
4
Biomarkers
2
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.